A new PTSD drug could break a two-decade drought in treatment options—if the FDA doesn’t let the bureaucracy and big pharma gamesmanship get in the way, as Americans demand real results for our veterans and working families, not more government inaction and price gouging.

At a Glance

• FDA advisory committee will review brexpiprazole plus sertraline for PTSD on July 18, 2025, the first new PTSD drug up for approval in over 20 years.
• The current PTSD treatment landscape is woefully outdated, with only two FDA-approved drugs—both SSRIs—since the 1990s.
• Phase 3 trials show the new combination therapy provides statistically significant symptom relief over existing options, but the cost is sky-high.
• Big pharma and insurers brace for a fight over access, cost, and whether the FDA will finally approve something that actually helps patients instead of padding bureaucratic stats.

FDA Prepares to Decide: Will Veterans Finally Get Relief?

For over two decades, the pharmaceutical giants and bureaucratic regulators have left PTSD sufferers—many of them American veterans—dangling with treatments that barely move the needle. The only FDA-approved medications, sertraline and paroxetine, have been collecting dust since the last century, while millions of Americans struggle through debilitating symptoms and the government hands out platitudes at VA press conferences. Now, Otsuka Pharmaceutical and Lundbeck are pushing to break the logjam with brexpiprazole (Rexulti), a drug already used for depression and schizophrenia, combined with sertraline. The FDA’s much-criticized Psychopharmacologic Drugs Advisory Committee is set to review the application on July 18, 2025—a date that could mark a rare victory for common sense, if they don’t find another way to slow-walk it or price average Americans out of the market.

The phase 3 clinical trial, recently published in a top medical journal, showed that this new combination therapy delivers a statistically significant reduction in PTSD symptoms compared to sertraline alone. That’s a big deal: for the first time in two decades, the science actually points toward a treatment that could give real, measurable relief. The stakes are sky-high for veterans, first responders, and all Americans who’ve paid the price for bureaucratic inertia and pharmaceutical price gouging. But will the FDA, under pressure from insurers and entrenched interests, finally deliver something besides empty promises?

Watch a report: Brexpiprazole + Sertraline A New Hope for PTSD Treatment

Big Pharma, Big Prices, and the Battle for Access

If you thought the price tag for progress would be reasonable, think again. Brexpiprazole clocks in at $1,471.50 per month—before insurance even gets involved and starts its usual shell game. Otsuka offers a savings program, but let’s not pretend that band-aid will cover the gaping wound of American healthcare costs. The real question: will insurers cover this new therapy, or will they leave patients twisting in the wind, forced to choose between their health and their bank account? And how long before the government steps in with more “cost controls” that end up limiting access even further?

As always, the usual suspects are circling—pharmaceutical lobbyists, insurance actuaries, government bean-counters—each angling to protect their slice of the pie. Meanwhile, PTSD patients and their families get to watch the circus and pray for an outcome that actually puts their needs ahead of corporate profits and bureaucratic red tape. If the FDA actually approves this therapy, it’ll be a miracle on par with the drug itself.

Expert Opinions: Hope, Hype, and the Need for Real Change

Leading psychiatrists like Dr. Roger McIntyre have called the trial results “positive and compelling,” finally acknowledging the “tremendous unmet need” in PTSD treatment. For once, the experts seem to agree with what everyday Americans have been shouting for years: the old system isn’t working, and patients deserve better. Dr. Elspeth Ritchie points out that adjunctive antipsychotics like brexpiprazole have been used for depression, but robust evidence for PTSD has always been lacking—until now.

Still, not everyone is convinced. Some academics warn that the long-term safety data just aren’t there, and it’s unclear whether the benefits of brexpiprazole are unique to its pairing with sertraline or could work with other antidepressants. Of course, in today’s climate, “more research” is often code for “more delays.” Americans know stalling when they see it, and they’re tired of bureaucrats and experts using uncertainty as an excuse to do nothing.